Talcum Powder lawsuit update

Verified snapshot

The facts that anchor this dossier

The largest active federal MDL combines old product-use histories, contested ovarian-cancer and mesothelioma theories, evolving asbestos-testing policy, and years of bankruptcy detours. This is the evidence-first version without a settlement calculator.

Federal proceeding

MDL 2738

District of New Jersey before Judge Michael A. Shipp.

Pending federal actions

68,435

JPML count as of July 1, 2026—the largest active federal MDL by pending actions.

Historical actions

71,121

Federal MDL total through July 1, 2026; state-court litigation is not included.

Core alleged injuries

Ovarian cancer and mesothelioma

Disease theory, exposure route, product history, and evidence differ; the categories should not be collapsed.

FDA 2023 sample result

0 of 50 detected asbestos

A targeted market sample, not proof about every talc product, mine, lot, or historical period.

Documented chronology

How the litigation reached this point

One MDL, but not one scientific question

MDL 2738 is often described as the talcum-powder case, but that shorthand hides materially different theories. Ovarian-cancer actions commonly allege repeated perineal use and biological movement or inflammatory effects. Mesothelioma actions typically focus on alleged asbestos contamination and inhalation. Product, formulation, lot, mine source, route of exposure, duration, diagnosis, and latency can differ. A headline about one disease should not be silently applied to the other.

The JPML centralized recurring pretrial issues; it did not find that talc caused cancer or that all products contained asbestos. The District of New Jersey currently identifies Judge Michael A. Shipp and Magistrate Judge Rukhsanah L. Singh as presiding judges. With 68,435 pending actions in July 2026, it is the largest active MDL by pending count, but size measures administration—not the strength or value of any particular claim.

The ovarian-cancer literature is genuinely mixed

Case-control studies have often reported modest associations between genital talc use and ovarian cancer, while prospective cohorts have generally been less supportive. A 2020 pooled analysis combined 252,745 women from four U.S. cohorts and found no statistically significant association between genital powder use and incident ovarian cancer. The authors also cautioned that the study might have been underpowered to detect a small increase. This pattern—different results across study designs—is why a single relative-risk number is misleading.

Recall bias can affect case-control research because people are asked to reconstruct use after diagnosis. Cohort studies reduce that problem by recording exposure before disease but may still misclassify product composition, frequency, location of use, or changes over decades. Epidemiology estimates population patterns; it does not identify fibers in a person's tissue, establish the contents of a historical product lot, or prove specific causation.

Talc and asbestos are related in geology, not interchangeable

FDA explains that talc and asbestos are distinct naturally occurring minerals that can occur near one another. Asbestos is a known carcinogen when inhaled, so contamination control and testing are central. In the agency's 2023 assignment, polarized-light and transmission-electron microscopy found no asbestos in 50 selected talc-containing cosmetic samples. That is reassuring for the samples tested, not a certificate covering every brand, historical lot, or mining source.

The limits are visible in later regulatory activity. In 2024, an FDA-posted recall covered specified Dynacare baby powder lots after routine sampling found asbestos. FDA proposed standardized testing methods in December 2024, then withdrew that proposal in November 2025 because comments warranted more assessment. Withdrawal means the agency returned to further consideration; it is not a safety finding for or against all talc cosmetics.

Bankruptcy detours changed procedure, not medical proof

Corporate restructuring and bankruptcy proceedings repeatedly interrupted the path of talc litigation. The 2024 Red River Talc Chapter 11 sought an aggregate bankruptcy route for ovarian and gynecological cancer claims. In March 2025, the bankruptcy court denied confirmation and dismissed the case. Separate federal court materials later discussed voting and solicitation concerns arising from that proceeding.

A bankruptcy dismissal is not a jury verdict on whether talc caused a claimant's disease, and it does not set an MDL value. It changes the forum and proposed resolution mechanism. The federal MDL remains listed as active, while numerous state-court proceedings follow their own tracks. Readers should distinguish bankruptcy orders, MDL case-management orders, state verdicts, and negotiated resolutions; each answers a different legal question.

The records that make this personal rather than generic

Long latency and changing product formulations make contemporaneous records valuable. Product photographs, purchase history, household use patterns, application location, approximate years and frequency, employment exposure history, pathology, and oncology records may help reconstruct facts. For mesothelioma, other occupational or household asbestos sources may be investigated. For ovarian cancer, histology, reproductive history, family history, and other risk factors may enter the analysis.

None of those facts can be converted responsibly into a public payout estimate. Limitation rules vary, defendants and products differ, and pending motions can alter viable theories. The official JPML count includes only federal actions assigned to the MDL; it omits state cases and does not show how many actions will be tried, dismissed, remanded, or resolved. This dossier therefore reports process and evidence without promising qualification, timing, or money.

Reader questions

Frequently asked questions